Oleksandr Lutsenko/Dreamstime
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime
Biontech Pfizer Covid 19 Vaccine Vial Syringe Needle Oleksandr Lutsenko Dreamstime

BioNTech Boosts 2021 Vaccine Supply Forecast to 2 Billion Doses

Jan. 11, 2021
The German company that developed the COVID-19 vaccine in cooperation with Pfizer is opening a new German factory to boost production.

German company BioNTech, which developed the first coronavirus vaccine approved in the West, said Monday it expects to produce two billion doses in 2021, up from the 1.3 billion previously forecast.

"We now believe that we can potentially deliver approximately 2 billion doses in total by the end of 2021, which incorporates the updated six-dose label," said the company, referring to an additional dose that could be extracted from each vial of the vaccine.

European regulators last week approved doctors drawing six doses from each vial, boosting dosage capacity by 20 percent.

The Mainz-based company, which developed the jab with US giant Pfizer, is planning to open a new factory in Marburg, Germany, in February, expected to ramp up production capacity by 750 million doses a year. 

The site will join five other sites in Germany, Belgium and the US shared with Pfizer.

The company said it had shipped nearly 33 million doses by January 10, more than a month after Britain became the first Western nation to approve any vaccine on December 2.

BioNTech's announcement comes after the EU agreed to raise its orders of the vaccine by 200 million doses, with an option for another 100 million. 

But the vaccination rollout has been criticised across Europe, with sluggish starts in nations like France and the Netherlands.

The company added that Covid-19 will "likely become an endemic disease", and that vaccines would need to fight against the emergence of new viral variants and a "naturally waning immune response".

The German company said last week that studies show its vaccine works against the new mutation found in variants uncovered in Britain and South Africa. 

Copyright Agence France-Presse, 2020

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!